Effects of Intermittent Hypoxia-Hyperoxia in Older Adults

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65-90
SponsorSierra Varona SL

About this trial

The supply of oxygen is essential for energy production, recovery from efforts, and human life. Intermittent Hypoxia-Hyperoxia Exposure (IHHE) is a novel technique in which the subject is exposed to a respiratory environment with reduced oxygen fraction, controlled through a specific software, using a facial mask and a hypoxic generation device. The objective of this study is to determine if there is a relationship between intermittent hypoxia-hyperoxia exposure and cardiorespiratory condition, blood pressure, and arterial oxygen saturation.

According to our hypothesis, acute IHHE in elderly adults may influence cardiorespiratory condition, inflammatory biomarkers, blood pressure, and arterial oxygen saturation.

The study will be conducted as a randomized clinical trial. The subjects will be divided into two groups: the experimental group will undergo an IHHE session, breathing air with an oxygen concentration (FiO2) ranging from 10-14% for 1-5 minutes, with 1-3 minutes of rest in hyperoxia (FiO2 30-40%) for a total of 4-8 cycles, based on their acute response to hypoxia. The sham group will undergo a 5-cycle protocol with an FiO2 of 21%.

Both groups will follow a 6-week protocol with three weekly sessions (Monday, Wednesday, and Friday).

Eligibility criteria

Qualifiers

Being over 65 years old.

Having no previous experience in hypoxic training.

Engaging in less than 150 minutes of physical activity per week.

Disqualifiers

Having any pathology that prevents the subject from being independent in terms of walking and functionality.

Subjects with impaired cognitive abilities.

Subjects with pulmonary hypertension, decompensated heart or respiratory disease.

To have or have had cancer

Trial design

Treatments tested in this trial

  • Device: Hypoxic Gas Mixture
  • Sham Hypoxic-Hyperoxic exposure

Treatment groups

16 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Sierra Varona SL

Lead sponsor

Universidad Europea de Madrid

Collaborator